Aruna Mani

1.5k total citations · 1 hit paper
28 papers, 982 citations indexed

About

Aruna Mani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Aruna Mani has authored 28 papers receiving a total of 982 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Aruna Mani's work include Advanced Breast Cancer Therapies (15 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (10 papers). Aruna Mani is often cited by papers focused on Advanced Breast Cancer Therapies (15 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (10 papers). Aruna Mani collaborates with scholars based in United States, Spain and United Kingdom. Aruna Mani's co-authors include William E. Carson, Cristina Saura, Sung‐Bae Kim, Julie M. Roda, Sherene Loi, Michelino De Laurentiis, Francisco J. Esteva, Monika Patre, Amy Lehman and Robin Parihar and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Aruna Mani

27 papers receiving 976 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

2020 280 citations Leisha A. Emens, Francisco J. Esteva et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aruna Mani United States	15	725	312	267	218	202	28	982
Abraham C.F. Leung United States	9	768 1.1×	258 0.8×	202 0.8×	326 1.5×	199 1.0×	17	969
Debora Pezzuolo Italy	6	566 0.8×	344 1.1×	139 0.5×	487 2.2×	312 1.5×	13	950
H. David Inzunza United States	8	798 1.1×	483 1.5×	156 0.6×	79 0.4×	225 1.1×	12	1.0k
France Blanchard France	8	448 0.6×	222 0.7×	148 0.6×	192 0.9×	231 1.1×	14	736
Aude Lamy France	14	499 0.7×	188 0.6×	223 0.8×	196 0.9×	364 1.8×	28	931
Noah Goodman United States	10	381 0.5×	162 0.5×	275 1.0×	76 0.3×	116 0.6×	12	646
A. Lambiase Italy	17	613 0.8×	102 0.3×	181 0.7×	146 0.7×	297 1.5×	55	899
Konstantinos Tsaparikos United States	7	515 0.7×	185 0.6×	225 0.8×	86 0.4×	230 1.1×	11	682
R. Islam United States	7	531 0.7×	90 0.3×	277 1.0×	97 0.4×	207 1.0×	8	725
Monika Patre Switzerland	14	1.0k 1.4×	147 0.5×	324 1.2×	500 2.3×	140 0.7×	24	1.2k

Countries citing papers authored by Aruna Mani

Since Specialization

Citations

This map shows the geographic impact of Aruna Mani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aruna Mani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aruna Mani more than expected).

Fields of papers citing papers by Aruna Mani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aruna Mani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aruna Mani. The network helps show where Aruna Mani may publish in the future.

Co-authorship network of co-authors of Aruna Mani

This figure shows the co-authorship network connecting the top 25 collaborators of Aruna Mani. A scholar is included among the top collaborators of Aruna Mani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aruna Mani. Aruna Mani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Turner, Nicholas C., Rebecca Dent, Joyce O’Shaughnessy, et al.. (2021). Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Research and Treatment. 191(3). 565–576. 64 indexed citations

Schmid, Peter, Delphine Loirat, Peter Savas, et al.. (2021). Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC). Cancer Research. 81(4_Supplement). PD14–3. 1 indexed citations

Savage, Heidi, Mafalda Oliveira, Carlos H. Barrios, et al.. (2021). Abstract PS5-06: Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial. Cancer Research. 81(4_Supplement). PS5–6.

Turner, Nicholas C., Rebecca Dent, Joyce O’Shaughnessy, et al.. (2020). 283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial. Annals of Oncology. 31. S354–S355. 10 indexed citations

Wongchenko, Matthew, Sung‐Bae Kim, Cristina Saura, et al.. (2020). Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology. 4(4). 1012–1024. 13 indexed citations

Emens, Leisha A., Francisco J. Esteva, Mark Beresford, et al.. (2020). Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. The Lancet Oncology. 21(10). 1283–1295. 280 indexed citations breakdown →

Dent, Rebecca, Mafalda Oliveira, Steven J. Isakoff, et al.. (2020). 139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology. 31. S64–S65. 14 indexed citations

Schmid, Peter, Sherko Kümmel, Delphine Loirat, et al.. (2020). Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC). Senologie - Zeitschrift für Mammadiagnostik und -therapie. 3 indexed citations

Schmid, Peter, Delphine Loirat, Peter Savas, et al.. (2019). Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Research. 79(13_Supplement). CT049–CT049. 42 indexed citations

10.

Schmid, Peter, Delphine Loirat, Peter Savas, et al.. (2019). Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Clinical Trials. CT049–CT049. 1 indexed citations

11.

Emens, Leisha A., Francisco J. Esteva, Mark Beresford, et al.. (2019). Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC). Annals of Oncology. 30. v104–v104. 47 indexed citations

12.

Yardley, Denise A., Dianna Shipley, Patrick J. Ward, et al.. (2018). A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer. Clinical Breast Cancer. 19(1). 1–9. 7 indexed citations

13.

Hurvitz, Sara A., Julie Taguchi, David W. Chan, et al.. (2018). Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Therapeutic Advances in Medical Oncology. 10. 3861422379–3861422379. 25 indexed citations

14.

Shewade, Ashwini, Angela Hsieh, Aruna Mani, et al.. (2018). Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets).. Journal of Clinical Oncology. 36(15_suppl). 1037–1037. 5 indexed citations

15.

Yardley, DA, P. Chandra, Patrick J. Ward, et al.. (2016). Abstract P1-14-06: A phase II randomized study with eribulin/cyclophosphamide (ErC) and docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in HER2-negative breast cancer- Final analysis of primary endpoint and correlative analysis results. Cancer Research. 76(4_Supplement). P1–14. 1 indexed citations

16.

Zeichner, Simon B., Aruna Mani, Alberto J. Montero, et al.. (2015). Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. Breast Cancer Research and Treatment. 153(3). 617–624. 33 indexed citations

17.

Jaime‐Ramirez, Alena Cristina, Bethany L. Mundy-Bosse, Natalie Jones, et al.. (2011). IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production. The Journal of Immunology. 186(6). 3401–3409. 81 indexed citations

18.

Mani, Aruna, Julie M. Roda, Donn C. Young, et al.. (2008). A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Research and Treatment. 117(1). 83–89. 36 indexed citations

19.

Roda, Julie M., Robin Parihar, Amy Lehman, et al.. (2006). Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets. The Journal of Immunology. 177(1). 120–129. 100 indexed citations

20.

Mani, Aruna, et al.. (2004). Apoptosis of Multiple Myeloma. International Journal of Hematology. 80(3). 224–231. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact